4.8 Article

AGO4 suppresses tumor growth by modulating autophagy and apoptosis via enhancing TRIM21-mediated ubiquitination of GRP78 in a p53-independent manner

期刊

ONCOGENE
卷 42, 期 1, 页码 62-77

出版社

SPRINGERNATURE
DOI: 10.1038/s41388-022-02526-0

关键词

-

向作者/读者索取更多资源

This study discovered that AGO4 had low expression in non-small cell lung cancer patient tumor tissues and could suppress NSCLC cell proliferation and metastasis. The mechanism showed that AGO4 could interact with TRIM21 and GRP78, promoting ubiquitination of GRP78 and resulting in induced cell apoptosis and inhibited autophagy. Furthermore, p53 was found to have dominant effects on the TRIM21-GRP78 axis, and AGO4 may alternatively regulate this axis in p53-deficient cells. The study suggests that the AGO4-TRIM21-GRP78 axis may be a potential therapeutic target for p53-deficient tumor treatment.
Argonaute proteins, which consist of AGO1, AGO2, AGO3 and AGO4, are key players in microRNA-mediated gene silencing. So far, few non-microRNA related biological roles of AGO4 have been reported. Here, we first found that AGO4 had low expression in non-small cell lung cancer (NSCLC) patient tumor tissues and could suppress NSCLC cell proliferation and metastasis. Subsequent studies on the mechanism showed that AGO4 could interact with the tripartite motif-containing protein 21 (TRIM21) and the glucose-regulated protein 78 (GRP78). AGO4 promoted ubiquitination of GRP78 by stabilizing TRIM21, a new specific ubiquitin E3 ligase for promoting K48-linked polyubiquitination of GRP78 confirmed in this paper, which resulted in induced cell apoptosis and inhibited autophagy by activating mTOR signal pathway. Further studies showed that p53 had dominant effects on TRIM21-GRP78 axis by directly increasing the expression of TRIM21 in p53 wild-type cells and AGO4 may alternatively regulate TRIM21-GRP78 axis in p53-deficient cells. We also found that overexpression of AGO4 results in suppression of multiple p53-deficient cell growth both in vivo and vitro. Together, we showed for the first time that the AGO4-TRIM21-GRP78 axis, as a new regulatory pathway, may be a novel potential therapeutic target for p53-deficient tumor treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据